Aegerion CEO Talks Juxtapid Launch, Competitive Threats At BIO
This article was originally published in The Pink Sheet Daily
Executive Summary
Aegerion CEO Marc Beer outlined why he thinks Juxtapid will emerge as the first-line treatment of choice for the orphan lipid disease HoFH over Genzyme/Isis’ Kynamro despite its significantly higher cost during an interview at the BIO CEO & Investor conference; the two drugs are facing off to win patients in an ultra-niche market that could total just 3,000 patients in the U.S.